Mednet Logo
SpecialtiesRheumatology
Rheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

Would the need for infliximab/MTX/nonsteroidals to control initial irAE affect your decision to rechallenge these patients with ICI?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Johns Hopkins University School of Medicine

Infliximab and methotrexate are generally used in irAE grades 3 or 4, or in grade 2 irAEs that are refractory to initial treatment with steroids. Methotrexate is typically used for irAEs of the musculoskeletal system, such as inflammatory arthritis or myositis. Infliximab tends to be used in the set...

Under what circumstances would you consider low-dose radiation therapy for osteoarthritis in an older adult patient?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · LJA

Almost any and all circumstances.

When is the ideal time in the disease course to offer radiotherapy for Dupuytren's disease for the most optimal outcomes?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Inova Schar Cancer Institute

Radiotherapy is most effective when fibroblasts are actively proliferating, i.e., during the cellular or proliferative phase of the disease, when there is a palpable, progressive nodule or cord but no fixed contracture.Prospective German trials show that treating during this biologically active peri...

Would you consider re-irradiation for recurrence of Dupuytren's Contracture?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Providence Health, St. Joseph Hospital

Agree with @Dr. First Last, especially since the total doses used for treatment are widely variable (as low as 10 Gy all the way to 40 Gy), with clinical study evidence supporting a minimum dose of 21 Gy. Seegenschmiedt et al., PMID 11172962Due to dose constraints for the hand being about 60 Gy (no ...

What factors do you consider when advising a patient with lupus nephritis on the safety of becoming pregnant?

1
3 Answers

Mednet Member
Mednet Member
Rheumatology · Weill Cornell Medical College

I agree with Dr. @Dr. First Last's excellent suggestions (with just one exception!). I don't increase prednisone prophylactively for lupus pregnancy - I would only add or increase steroid if there is a flare. The risks of steroid in pregnancy impact both maternal and pregnancy outcomes, so we try to...

Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Johns Hopkins University School of Medicine

Grade 1 pneumonitis is defined as confined to one lobe of the lung or <25% of the total lung parenchyma, while grade 2 pneumonitis is defined as involving more than one lobe of the lung or 25-50% of the lung parenchyma. Grade 1 pneumonitis is typically an incidental finding on CT in an asymptomatic ...

Has the MAJESTY trial changed your approach to the rituximab versus obinutuzumab choice in a patient with newly diagnosed primary membranous nephropathy and nephrotic syndrome?

2 Answers

Mednet Member
Mednet Member
Nephrology · Johns Hopkins University

The Bottom Line: Recent landmark trials—MENTOR and MAJESTY—confirm that anti-CD20 therapies are superior to calcineurin inhibitors (CNIs) for the treatment of MN.Key Trial DataMENTOR: Demonstrated that RTX was noninferior to cyclosporine at 12 months, and decisively superior by 24 months (60% vs. 20...

Are there particular subsets of AAV patients in which avacopan is more effective?

1 Answers

Mednet Member
Mednet Member
Rheumatology · Director, Vasculitis Clinical Research Consortium

The following answer was jointly drafted by Dr. Peter Merkel and Dr. David Jayne:Patients in the ADVOCATE trial were stratified at entry according to time of diagnosis (new/relapsing), diagnosis (GPA/MPA), ANCA serotype (PR3/MPO), and background immunosuppressive (cyclophosphamide/rituximab) with re...

How do you interpret treatment response in the DISCOVER-2 Trial when patients were allowed to remain on up to 10mg of prednisone equivalent for disease control while on guselkumab?

3 Answers

Mednet Member
Mednet Member
Rheumatology · Leiden University Medical Center

The dependence on the use of systemic glucocorticoids may indeed be a good reason to change treatment. Especially in patients with psoriatic arthritis. So, if patients are unable to stop systemic glucocorticoids and there are still treatment options for the patient, this could be tried. It is diffic...

What specific criteria or patient conditions would make you hesitant to use fluoroquinolones early in the treatment course for managing MSSA joint infections with oral antibiotics?

3 Answers

Mednet Member
Mednet Member
Infectious Disease · Nebraska Medical Center

For MSSA joint infections, I have moved away from using FQ to using high-dose cephalosporins as a step-down therapy, particularly cefadroxil 1 g twice daily, given less frequent dosing/increased adherence. Considering the risk-benefit analysis, I prefer using FQ as an oral option in polymicrobial an...